$3.280
-0.333 (-10.14%)At close
- High
- 3.840
- Open
- 3.600
- VWAP
- 3.40
- Volume
- 61.95K
- Mkt Cap
- —
- Low
- 3.090
- Amount
- 210.82K
- EV/EBITDA, TTM
- 0.00
Organic Plant Health, Inc. produces, distributes, and sells organic based fertilizers and soil conditioners for the care and maintenance of residential and commercial lawns, gardens, and farms. The company's products include granular and liquid fertilizers, soil conditioners, and pest control products. It sells its products through retail partners in the North Carolina region. The company also operates a retail location in Matthews, North Carolina. It serves residential customers and commercial landscapers. Organic Plant Health, Inc. was incorporated in 2007 and is headquartered in Scottsdale, Arizona.
AI analysis of Organic Plant Health Inc (OPHI)
BuySophia Genetics (SOPH) is a good buy right now due to its current price of $8.21, which is significantly below the analyst price targets of $9 to $14. The company has shown a remarkable year-to-date change of +75.80% and a 52-week high of $8.98, indicating strong upward momentum. Additionally, the RSI is at 68.74, suggesting the stock is nearing overbought territory but still has room for growth. The main risk is the negative earnings per share of -0.30 reported in Q2 2026, which indicates ongoing losses, but the company's revenue growth of 27% year-over-year and partnerships with AstraZeneca provide a solid growth outlook.
Valuation Metrics
OPHI FAQ — answered by Alphio AI
Organic Plant Health, Inc. produces, distributes, and sells organic based fertilizers and soil conditioners for the care and maintenance of residential and commercial lawns, gardens, and farms. The company's products include granular and liquid fertilizers, soil conditioners, and pest control products. It sells its products through retail partners in the North Carolina region. The company also operates a retail location in Matthews, North Carolina. It serves residential customers and commercial landscapers. Organic Plant Health, Inc. was incorporated in 2007 and is headquartered in Scottsdale, Arizona. It operates in the Basic Materials sector.
Sophia Genetics (SOPH) is a good buy right now due to its current price of $8.21, which is significantly below the analyst price targets of $9 to $14. The company has shown a remarkable year-to-date change of +75.80% and a 52-week high of $8.98, indicating strong upward momentum. Additionally, the RSI is at 68.74, suggesting the stock is nearing overbought territory but still has room for growth. The main risk is the negative earnings per share of -0.30 reported in Q2 2026, which indicates ongoing losses, but the company's revenue growth of 27% year-over-year and partnerships with AstraZeneca provide a solid growth outlook.
Community
More ↗No posts yet
Sign up or log in to join the discussionRelated articles
- How to Invest in IPOs: What SpaceX, Cerebras and the Anthropic Debut Teach Investors in 2026How to invest in IPOs as Anthropic lists: how retail allocations work, what IPO data show about returns, SpaceX and Cerebras lessons, lockups and index rules.
- Is the Stock Market Overvalued? Why CAPE Says Yes and the Forward P/E Says Not So FastIs the stock market overvalued? The CAPE is near 39 but the forward P/E is 17.7. What each measure says, the bond yield test, and how to invest in late 2026.
- High Yield Bonds in 2026: What CCC Credit Stress Means for Income Investors and StocksHigh yield bonds pay about 8% in 2026, but CCC spreads have blown out. Learn what credit spreads signal for stocks and how to invest in junk bonds wisely.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.